Quest Diagnostics and Laboratory Corporation of America both said during their presentations at the 42nd JP Morgan Healthcare Conference on Tuesday that the environment for hospital lab acquisitions continues to be extremely strong and that they see such deals as significant growth opportunities. The companies noted that higher capital costs and competing priorities are leading more and more hospital systems to offload their laboratory businesses, even in cases where those businesses are profitable. “If they have to make a choice of [where to put capital], they are going to put it into surgery instead of lab,” said Labcorp Chairman, President, and CEO Adam Schechter.
Read the full article: Quest, Labcorp Report Strong Acquisition Pipelines, Positive Signs on Pricing at JP Morgan //
Source: https://www.360dx.com/clinical-lab-management/quest-labcorp-report-strong-acquisition-pipelines-positive-signs-pricing-jp